MDACC Study No:2004-0271 ( NCT No: NCT00472056)
Title:Randomized trial using standard dose versus high dose rituximab in addition to autologous transplantation with BEAM for patients with Diffuse Large B cell lymphomas.
Principal Investigator:Chitra M. Hosing
Treatment Agent:Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if giving high dose
rituximab with transplantation and high dose chemotherapy is more effective
than giving standard dose rituximab with transplantation and high dose
chemotherapy in the treatment of non-Hodgkin's lymphoma. The safety of these
two treatments will be compared. The safety of giving autologous
transplantation in patients with non-Hodgkin's lymphoma who are older than 65
years of age will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Carmustine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Hospital stay approximately 3 weeks. Houston stay 6 weeks
Supported By:N/A
Return Visit:Every 3 months till 6 months after transplantation, then every 6 months for 3
Home Care:Patients may receive intravenous fluids, intravenous antibiotics and injections
of growth factors at home

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Chitra M. Hosing
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults